I7P-MC-DSAG Ulcerative Colitis Study
An adaptive, dose-ranging, Phase 2 study of eltrekibart and mirikizumab for the treatment of adult patients with moderately to severely active ulcerative colitis
Site Resources
Enter your PIN code to access the study site. This website is for study site staff only. Please do not share your PIN or the website content with study participants.